News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

   
Date Title Source
2022-12-02 4:6:28 am Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) BusinessWire
2022-12-02 4:0:0 am Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) Business Wire
2022-11-30 5:8:0 pm Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire
2022-11-30 1:0:0 pm Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit Business Wire
2022-11-29 4:0:0 am Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer Business Wire
2022-11-11 2:24:17 am Adicet Bio Third Quarter 2022 Earnings: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021) Simply Wall St.
2022-11-08 1:10:0 pm Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates Business Wire
2022-11-07 5:0:0 am Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Business Wire
2022-11-03 6:0:0 am Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) Business Wire